Solos buys Lifeline cancer detection line:
This article was originally published in Clinica
Executive Summary
Endoscopic instrumentation and medical imaging solutions developer Solos Endoscopy is acquiring Lifeline Biotechnologies' line of early cancer detection products, which include the MastaScope, First Warning system and OvaScope, for $4m in an all-stock transaction. Boston, Massachusetts-based Solos will also pay Lifeline, of Reno, Nevada, royalties on sales exceeding $4m. Lifeline's MastaScope, designed for the early detection of breast cancer, is available internationally, while the company's First Warning system - also used for breast cancer diagnosis - and the OvaScope - designed to detect ovarian cancer - are still under development.